Premium
Use of Healthy Volunteers Drives Clinical Oncology Drug Development Decision Making
Author(s) -
Iwamoto M,
Ian R,
Wagner J A
Publication year - 2012
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.2012.157
Subject(s) - clinical pharmacology , drug development , medicine , clinical oncology , pharmacodynamics , volunteer , drug , oncology , pharmacology , population , pharmacokinetics , intensive care medicine , cancer , agronomy , biology , environmental health
The development of noncytotoxic oncology therapeutics has opened the opportunity for clinical investigation beyond cancer patients. Utilization of the healthy‐volunteer population has provided valuable safety, pharmacokinetic, drug interaction, and pharmacodynamic data that have greatly aided oncology clinical drug investigation. However, healthy‐volunteer studies and application of these data have not yet been optimally employed. Data from healthy‐volunteer studies can impact dose, targets, and end points for program focusing. Clinical Pharmacology & Therapeutics (2012); 92 5, 571–574. doi: 10.1038/clpt.2012.157